Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS
Clinical trial NCT03495713 · TERMINATED
Trial details
- NCT number
- NCT03495713
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-02
- Primary completion
- 2022-04-20
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.